CardiacAssist Builds a Bridge to the Next Bridge

CardiacAssist operates in the market for acute heart failure, with TandemHeart a pump designed to reverse multi-organ failure, to help the heart recover, or at the very least, keep patients alive so they can move on to the next therapeutic option. A lot has happened since Start-Up spoke with CardiacAssist back in 2002. The company's TandemHeart gained 510(k) clearance in 2003, and by January 2009, more than 1,500 TandemHeart procedures had been performed. The pace of adoption is accelerating. Now, with sales of $10 million, and a steady 40% growth rate, the company is no longer dependent upon venture capital.

The road to heart failure is on a steady decline. Patients get progressively worse as time goes by and that means they need different therapeutic options depending on where they are in their journey. Today’s treatments for chronic heart failure leave large gaps in the continuum of care; drugs are used at the early stages, and at the end stage a heart transplantation is the only option. In between the extremes, says Michael Garippa, CEO of CardiacAssist Inc., there is a need for technologies to support the failing hearts of patients "for hours, days, weeks, and years; cardiac assist devices to reverse multi-organ failure, to help the heart recover, or at the very least, keep patients alive so they can move on to the next therapeutic option," he says.

CardiacAssist aims to fill those gaps. Its goal is to create a bridge to a decision or a bridge to another bridge, with TandemHeart a percutaneous centrifugal pump for the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight